Bicyclic compounds as ATX inhibitors

A compound of formula (II):

• wherein:
• R1 is selected from the group consisting of:
• i) phenyl substituted by R3, R4 and R5,
• ii) phenyl-C1-6-alkyl substituted by R3, R4 and R5,
• iii) phenoxy-C1-6-alkyl substituted by R3, R4 and R5,
• iv) phenyl-C2-6-alkenyl substituted by R3, R4 and R5,
• v) phenyl-C2-6-alkynyl substituted by R3, R4 and R5,
• vi) pyridinyl substituted by R3, R4 and R5,
• vii) pyridinyl-C1-6-alkyl substituted by R3, R4 and R5,
• viii) pyridinyl-C2-6-alkenyl substituted by R3, R4 and R5,
• ix) pyridinyl-C2-6-alkynyl substituted by R3, R4 and R5,
• x) thiophenyl substituted by R3, R4 and R5,
• xi) thiophenyl-C1-6-alkyl substituted by R3, R4 and R5,
• xii) thiophenyl-C2-6-alkenyl substituted by R3, R4 and R5, and
• xiii) thiophenyl-C2-6-alkynyl substituted by R3, R4 and R5;
• Y is selected from the group consisting of:
• x) C3-8-cycloalkyl-C1-6-alkyl,
• xi) C3-8-cycloalkyl-C1-6-alkoxy,
• xii) C3-8-cycloalkoxy,
• xiii) C3-8-cycloalkoxy-C1-6-alkyl,
• xiv) C1-6-alkylamino,
• xv) C1-6-alkylcarbonylamino,
• xvi) C3-8-cycloalkylcarbonylamino,
• xvii) C1-6-alkyltetrazolyl,
• xviii) C1-6-alkyltetrazolyl-C1-6-alkyl, and
• xix) heterocycloalkyl-C1-6-alkoxy;
• R4 and R5 are independently selected from the group consisting of:
• i) H,
• ii) halogen,
• iii) hydroxy,
• iv) cyano,
• v) C1-6-alkyl,
• vi) C1-6-alkoxy,
• vii) C1-6-alkoxy-C1-6-alkyl,
• viii) halo-C1-6-alkoxy,
• ix) halo-C1-6-alkyl,
• x) hydroxy-C1-6-alkyl,
• xi) C3-8-cycloalkyl,
• xii) C3-8-cycloalkyl-C1-6-alkyl,
• xiii) C3-8-cycloalkyl-C1-6-alkoxy,
• xiv) C3-8-cycloalkoxy,
• xv) C3-8-cycloalkoxy-C1-6-alkyl,
• xvi) C1-6-alkylcarbonylamino,
• xvii) C3-8-cycloalkylcarbonylamino,
• xviii) C1-6-alkyltetrazolyl,
• xix) C1-6-alkyltetrazolyl-C1-6-alkyl, and
• xx) heterocycloalkyl-C1-6-alkoxy;
• R6 is selected from the group consisting of:
• i) H,
• ii) C1-6-alkyl, and
• i) —OC(O)—, and
• ii) —C(O)—;
• A is selected from the group consisting of:
• i) —O—, and
• ii) —S—;
• X is selected from the group consisting of:
• i) —N—, and
• ii) —CH—;
• W is selected from the group consisting of:
• i) —C(O)—, and
• ii) —S(O)2—;
• R2 is selected from the ring systems O, AO, AW, AX, AY and AZ;
• R3 is selected from the group consisting of:
• i) halogen,
• ii) hydroxy,
• iii) cyano, C1-6-alkyl,
• iv) C1-6-alkoxy,
• v) C1-6-alkoxy-C1-6-alkyl,
• vi) halo-C1-6-alkoxy,
• vii) halo-C1-6-alkyl,
• viii) hydroxy-C1-6-alkyl,
• ix) C3-8-cycloalkyl,
• iii) C3-8-cycloalkyl;
• m is 1;
• n is 1 or 2;
• and
• r is 1, 2 or 3;
• or a pharmaceutically acceptable salt thereof.